BANF1 and non-small cell lung carcinoma: The presence of BAF/PBAF gene mutations was associated with improved outcome on immunotherapy in almost all carcinomas types except in non-small cell lung cancer (NSCLC), unknown primary carcinoma and renal cancer even if the effect for some cancer types did not reach statistical significance, due to limited sample size.